Menu
Scroll to Top
Locations
San Diego, CA, USA
Operator of a precision oncology biotechnology company intended to develop targeted therapies for cancer patients with specific DNA repair deficiencies. The company offers a first-in-class small molecule therapy, ITX-121, designed to selectively kill cancer cells deficient in the nucleotide-excision repair pathway, enabling customers particularly those with solid tumors identified through biomarker screening, to benefit from a highly targeted, potentially less toxic treatment approach that personalizes cancer care.
Something looks off?